Search This Blog

Showing posts with label Alexis Stroud. Show all posts
Showing posts with label Alexis Stroud. Show all posts

Monday, December 13, 2010

Auditing Your Aggregate Spend Program

Written by Alexis Stroud, Director Quality and Compliance, QPharma

1. What components of the audit process need to be implemented to ensure compliance with state aggregate spend and Healthcare Reform regulations?

In order to comply with state aggregate spend and healthcare reform legislation and regulations, you need to have policies, procedures, systems, controls, and monitoring and auditing processes designed to maintain data integrity and compliance with the various state and federal reporting requirements.

Life science companies must clearly understand and interpret the regulatory challenges to comply with each States’ reporting requirements, as well as begin preparation for the Patient Protection and Affordable Care Act (PPACA) – and possibly new state legislation. Based on these interpretations, their policies, procedures, monitoring controls, and auditing steps need to be developed and implemented to ensure reporting compliance is maintained.  This becomes even more challenging for a life science company, because the necessary data and systems are generally not centrally located or maintained (i.e. a cross-functional effort). In addition, the required data elements required to comply with the current Federal reporting requirements may be incomplete or non-existent within these systems.

Using a process-based audit approach enables a company to understand all of its interactions with Healthcare Providers (HCPs) and how those interactions are performed and recorded within its existing systems.  This type of assessment delivers a detailed understanding of the current environment in which your company is operating; identifies policy and procedure gaps, control weaknesses, and opportunities to implement industry best practices; and positions your company to ensure accurate and complete state and federal disclosure.
Note: Some of the state laws (NV and MA, for example) require certification that a manufacturer has conducted audits as part of its compliance program.



What should your Auditing and Monitoring Program consider?
  •  Is the process documented?  What is the process for reporting findings?
  • Does the compliance auditing and monitoring program incorporate key approval points such as HCP credentialing, needs assessment, payment authorization, and reporting accuracy?
  • Have you built into the formal compliance audits a degree of independence?
  • Are audits performed at least annually?
  • How aware are your Internal Audit teams of the requirements of the state and federal regulations.  
  • When reviewing past audit reports, how comprehensive were those reviews?  Were findings investigated and closed out?

Things to consider when auditing your aggregate spend program:
  • Do you have a Federal- and State-specific reporting policy?  Is it adequate and is it being followed?  How are you keeping up to date with the changing legislation and regulations and how is that information being communicated within the organization and to any third party providers?
  • Do you have assessments of third party vendors?
    • Third party vendors are acting as agents of a Company. Their activity is ultimately the activity of the Company.
    • Monitoring/auditing should include activities of third party vendors.  Perform contract reviews.
    • Third party vendors should be informed of this requirement and will have to potentially provide data and other documentation for the audit.
  • Do you understand the underlying data controls?
    • Process – How is data captured, approved, and updated?
    • Systems – What systems are the data maintained in and what are the relevant controls and validation procedures?
    • Data – What data elements are available to meet the reporting requirements?
    • Procedures – What processes are necessary to capture accurate and complete relevant data?
  • What are your data collection challenges? How can you improve current processes to address these challenges?
  • Are there enough resources within your organization to perform various data gathering, validation, and reporting functions?
  • Have you had any prior incomplete or inaccurate State reporting filings?
  • What tools/procedures (checklists, sign-offs, sub-certification process) and monitoring controls are in place to address the day-to-day process designed to enhance compliant state reporting?
    •  ensure accuracy of data through consistent and efficient data review
    • identify and investigate outliers and compliance red flags
  • Have you tested any system-based tools to ensure they are working properly?
  • Is your system flexible enough to change and adapt over time with new/updated laws and are you collecting data at the most granular level?
  • Has training been provided to all levels of the organization related to the current and future reporting environment requirements, company policies and standard operating procedures, and monitoring and auditing techniques?
  • Is the company using the information obtained for state reporting requirements to enhance business operations, as well as overall corporate compliance?
  • Do you have disciplinary actions for employees that do not comply with your procedures?

Tuesday, November 23, 2010

Happy Thanksgiving! Don't Miss Our End of Year Events!

Will you be attending any of these events? We hope you will be joining our Subject Matter Experts as they share their insight and expertise on some of the most pressing issues before the close of the year!

IPA'S Good Laboratory Practices
November 30 – December 1, 2010 - Montreal, Canada
Introduction, Requirements and Tools for Implementation
 You've probably met Nancy Tomoney at past conferences - we hope you got a chance to view her presentation at RAPS 2010! If not, please introduce yourself, as Nancy will be attending and presenting at IPA's GLP conference in Canada this year. She joins a high profile panel of speakers with talks on Testing and Reporting Controls, among others.

Click here for more information, or to register for this event.

 

BIOCOM Presents: Off Label Promotion
November 30, 2010 - San Diego, California

Managing the Regulatory Compliance and Products Liability Risks
Alexis Stroud, our Director of Quality and Compliance, is another popular face on our speaking circuit. She is jointly presenting with Medmarc on this topic for BIOCOM members, as well as non-members! This is a must-see presentation that will cover, among other topics:

-Prosecution of off-label promotion as a form of Medicare fraud
-FDA guidance on the dissemination of medical and scientific journal articles;
-The impact of off-label promotion on certain, key products liability defenses; and
-Best practices for preventing off-label promotion.

Click here for more information, or to register for this event.


MASSMedic FDA Update
December 1, 2010 - Waltham, Massachusetts
Important FDA Regulatory News and Policies covered by Dr. Jeffrey Shuren, Director of the Center for Device and Radiological Health
When the FDA has something to say, a lot of people will be listening! So register early and claim your seat at this pivotal end-of-year program. In conjunction with the American Society for Quality/New England Biomedical Discussion Group & the Regulatory Affairs Professional Society/Boston Chapter, QPharma's Fred Sperry and Bruce Fieggen (crowd favorites!) will be giving you some inside info on:
- Project Management - What We All Need to Know
- 21 CFR Part 11 Compliance - What's New


On behalf of QPharma's entire team, we wish you a Happy, Safe, and Fun Thanksgiving!

Monday, October 25, 2010

It’s All About State Compliance

 We are approaching the end of 2010, and by now, you should have filed your state aggregate spend reports for D.C., Massachusetts, Maine, Minnesota, Vermont, and West Virginia* .  You are most likely also preparing for the Physician Payment Sunshine Provision, included in the Patient Protection and Affordable Care Act (PPACA).  But are you aware of the numerous other state laws and regulations that affect the sales and marketing teams within your organization?  In this post, I will review some of the state legislation that you should be aware of including:

•    Compliance Programs
•    Sample Theft/Loss Reporting
•    Sample Transparency
•    Lobbying
•    Data Privacy
•    Representative Licensing

*Medical Device companies – You are not off the hook!  You too are required to track and report aggregate spend in CA (declaration of compliance), MA, and VT.  You will also be required to report under the federal PPACA in 2013.

Compliance Programs
The company must have a compliance program in place with certain elements. For example:
•    Adhere to, at a minimum, PhRMA Code (CA, MA, NV, CT)
•    Program must be in accordance with OIG Guidance (CA, CT)
•    Compliance Training (CA, CT, MA, NV, VT)
•    Compliance Monitoring (CA, CT, MA, NV, VT)

Sample Theft/Loss Reporting
Certain states require the reporting of sample thefts and/or losses in addition to federal reporting. For example:
•    Vermont and Washington require reporting immediately
•    Arkansas, Florida, Hawaii,  Indiana, Louisiana, Oregon, Wyoming require reporting within 3 working days
•    Colorado and Ohio require reporting within 30 days
•    New Mexico, North Dakota, South Carolina, and Virginia also have reporting requirements

Sample Transparency
Vermont’s Senate bill 88 (“SB88”) amends Vermont’s Pharmaceutical Marketing Disclosure Law by requiring manufacturers of prescribed products to disclose to the Vermont Attorney General’s Office all free samples of prescribed products provided to health care providers during the preceding calendar years.
•    “Sample” includes starter packs and coupons or other vouchers that enable an individual to receive a prescribed product free of charge or at a discounted price
•    This bill requires manufacturers to identify for each sample the product, recipient, number of units, and dosage
•    The first report is due on April 1, 2012 for the previous year's sampling activity

Lobbying
These laws require “lobbyists” to register and file a report that contains certain expenditure data. For example:
•    Colorado requires expenditures in excess of $50 to be reported
•    Florida requires a signed statement under oath of expenditures in excess of $25
•    Connecticut and Kentucky require a report for all expenditures
•    Louisiana requires reporting on expenditures that exceed $50 on any one occasion or $250 in a reporting period

Data Privacy
These laws require that certain prescriber data remain private. For example:
•    New Hampshire became the first state to pass a law that restricts the sale and use of prescriber data.
•    Vermont enacted a data privacy law which keeps prescriber data confidential unless practitioners request that their data be made available to the public.

There are also several other states that provide prescribers the option to “opt out” of being included in lists.  This includes lists of practitioner licensure data used for practitioner validation.  States also vary on the type of information they will provide within the list.

Representative Licensing
D.C. is currently the only state which requires all “detailers” doing business in DC to be licensed and held to a professional code of conduct. The bill also requires detailers to have an appropriate educational background.

Keep On Top of State Laws!
These were just a few of the state issues you should familiarize yourself with.  Others include mid-level prescriptive authority, distributing controlled substances, distributor licensing (wholesaler, virtual, 3PL, samples only), and pedigrees.  Many of the states also have fines for violating their laws (and investigate noncompliance). Pleading ignorance is not acceptable, so it’s important that you understand the legislation and know how to comply with it.

Looking for Regulatory Compliance help? Email us your questions at info@qpharmacorp.com!